Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: A 52-week open-label study.
about
Efficacy and safety of canagliflozin among patients with type 2 diabetes mellitus: A systematic review and meta-analysisBaseline characteristics and interim (3-month) efficacy and safety data from STELLA-LONG TERM, a long-term post-marketing surveillance study of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice.Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100 mg versus 300 mg canagliflozin: a systematic review and meta-analysis of published randomized controlled trialsSGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus.Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial.Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus.Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus.Effects of Baseline Blood Pressure and Low-Density Lipoprotein Cholesterol on Safety and Efficacy of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus.Factors Influencing Changes in Hemoglobin A1c and Body Weight During Treatment of Type 2 Diabetes With Ipragliflozin: Interim Analysis of the ASSIGN-K StudyEfficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from India.Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitusAn overview of the effect of sodium glucose cotransporter 2 inhibitor monotherapy on glycemic and other clinical laboratory parameters in type 2 diabetes patientsSGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials.Efficacy and safety of canagliflozin in type 2 diabetes mellitus: systematic review of randomized controlled trials.Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials.Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus.SGLT2 inhibitors in the pipeline for the treatment of diabetes mellitus in Japan.SGLT2 inhibitors in the management of type 2 diabetes.DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects.Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes.Canagliflozin: A Review in Type 2 Diabetes.Effectiveness of Ipragliflozin for Reducing Hemoglobin A1c in Patients With a Shorter Type 2 Diabetes Duration: Interim Report of the ASSIGN-K Study.Efficacy and tolerability of canagliflozin as add-on to metformin in the treatment of type 2 diabetes mellitus: a meta-analysis.Safety and efficacy of canagliflozin in Japanese patients with type 2 diabetes mellitus: post hoc subgroup analyses according to body mass index in a 52-week open-label study.Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes.Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin.Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, placebo-controlled, parallel-group comparative study.Long-term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus.Safety and efficacy of canagliflozin in elderly patients with type 2 diabetes mellitus: a 1-year post-marketing surveillance in Japan.Efficacy and safety of canagliflozin as add-on therapy to a glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week, open-label, phase IV study.Effect of Canagliflozin on Urinary Albumin Excretion in Japanese Patients with Type 2 Diabetes Mellitus and Microalbuminuria: A Pilot Study
P2860
Q26773558-12A5646C-2E7E-4A06-BDD5-4E0E8E236426Q31117903-6C46F077-5E8F-480C-B1FB-6C63EDE42A7FQ33567077-7942851A-3055-45A6-88A0-26DF2152CAEAQ33696974-AD359113-B826-4792-A658-9640E1EC2EE4Q33763305-2508B1DB-E80D-4ECC-B1D4-DBFE68160FF9Q33835558-F2ABE1C5-A6FC-4C79-AAE5-B976E95154E7Q33845734-A5AE5CCA-2B0B-41B1-A45D-45E9835E13F4Q36059244-CD174578-90A4-48F1-8E3A-D8AF063F7534Q36327116-64F0B290-034D-45AC-AF4A-7A887DC2386EQ36756191-D2C169C5-6381-41D6-83E5-6FC3B44E7569Q36867463-6B228395-4480-4D76-A4BD-BFF4473969F4Q37018165-51375E0F-8BD8-4156-9544-9246D976CAF5Q37114983-4C5C7976-BB34-4A81-A4A8-2D70E80A9C88Q38654762-013B3574-E136-499E-9809-B636DFF49973Q38663903-2D105BDB-4478-4F6C-B9C1-B05250DC8896Q38698155-551E8667-92A1-4277-9BDC-60D0A8255171Q38778064-99604B87-03A8-4AB3-ACCC-A91A8C2D530FQ38824557-7EBE0076-A574-4A36-A829-6FBEF6BFA42DQ38857523-7F911266-6D9C-433B-A6A8-E3B7FEAE44A9Q38902321-7E83D347-16E7-4E91-A29C-CA94D4D36A45Q39063447-998C94DF-216C-4C8F-9428-2B5DE3DA9740Q40081685-DCAB97A2-B3D1-4BBD-B035-191B25BB4064Q40091881-E9B3DEF8-337B-43BC-B9EE-ACCC89C0E4CEQ40633336-E8D45B9E-AF60-4D54-9F14-E0ED9102FD06Q41143357-C15E8FDA-8283-4447-8215-897D9691B32FQ47148933-DBD6A8EF-90C0-4C3D-8836-D26FCE8DFF25Q48228143-84A6B6C9-B9C6-4D63-924F-507ED9E99CF2Q48274765-0BCA7BC6-9E7D-48A9-97DB-903E66688D52Q48353746-20F7620F-ADAC-48A0-933C-66463162DE59Q50100476-005888B7-EF87-4D15-814E-A7F98A641A75Q51246665-AA500462-ED90-402B-BB12-79671E85AA1EQ57136996-BEF0132C-5E84-41C2-8149-701427E5EF0E
P2860
Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: A 52-week open-label study.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Efficacy and safety of canagli ...... s: A 52-week open-label study.
@ast
Efficacy and safety of canagli ...... s: A 52-week open-label study.
@en
type
label
Efficacy and safety of canagli ...... s: A 52-week open-label study.
@ast
Efficacy and safety of canagli ...... s: A 52-week open-label study.
@en
prefLabel
Efficacy and safety of canagli ...... s: A 52-week open-label study.
@ast
Efficacy and safety of canagli ...... s: A 52-week open-label study.
@en
P2093
P2860
P356
P1476
Efficacy and safety of canagli ...... es: A 52-week open-label study
@en
P2093
Hideki Kuki
Kazuoki Kondo
Toru Yoshinari
P2860
P304
P356
10.1111/JDI.12266
P577
2014-08-25T00:00:00Z